Abstract: The present invention relates to a method for classifying a diffuse large B-cell lymphoma (DLBCL) of a subject into a GCB-DLBCL or into a ABC-DLBCL comprising the step of determining the expression level of 10 genes in a tumor tissue sample obtained from the subject by performing a Reverse Transcriptase Multiplex Ligation dependent Probe Amplification (RT-MLPA) assay wherein the 10 genes are NEK6, IRF4, IGHM, LMO2, FOXP1, TNFRSF9, BCL6, TNFRSF13B, CCND2 and MYBL1.
Type:
Grant
Filed:
March 10, 2015
Date of Patent:
December 31, 2019
Assignees:
INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Rouen, Centre Henri Becquerrel